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ABSTRACT
Purpose: Despite high tumor mutationburden, immune
checkpoint blockade has limited efﬁcacy in SCLC. We hypothesized that poly (ADP-ribose) polymerase inhibition
could render SCLC more susceptible to immune checkpoint
blockade.
Methods: A single-arm, phase II trial (NCT02484404)
enrolled patients with relapsed SCLC who received durvalumab, 1500 mg every 4 weeks, and olaparib, 300 mg twice a
day. The primary outcome was objective response rate.
Correlative studies included mandatory collection of pretreatment and during-treatment biopsy specimens, which
were assessed to deﬁne SCLC immunephenotypes: desert
(CD8-positive T-cell prevalence low), excluded (CD8-positive
T cells in stroma immediately adjacent/within tumor), and
inﬂamed (CD8-positive T cells in direct contact with tumor).
Results: A total of 20 patients were enrolled. Their median
age was 64 years, and most patients (60%) had platinumresistant/refractory disease. Of 19 evaluable patients,
two were observed to have partial or complete responses
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(10.5%), including a patient with EGFR-transformed SCLC.
Clinical beneﬁt was observed in four patients (21.1% [95%
conﬁdence interval: 6.1%–45.6%]) with conﬁrmed responses or prolonged stable disease (8 months). The most
common treatment-related adverse events were anemia
(80%), lymphopenia (60%), and leukopenia (50%). Nine of
14 tumors (64%) exhibited an excluded phenotype; 21%
and 14% of tumors exhibited the inﬂamed and desert
phenotypes, respectively. Tumor responses were observed
in all instances in which pretreatment tumors showed an
inﬂamed phenotype. Of the ﬁve tumors without an inﬂamed
phenotype at baseline, no during-treatment increase in Tcell inﬁltration or programmed death ligand 1 expression
on tumor-inﬁltrating immune cells was observed.
Conclusions: The study combination did not meet the preset
bar for efﬁcacy. Pretreatment and during-treatment biopsy
specimens suggested that tumor immune phenotypes may be
relevant for SCLC responses to immune checkpoint blockade
combinations. The predictive value of preexisting CD8-positive
T-cell inﬁltrates observed in this study needs to be conﬁrmed
in larger cohorts.
Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.
Keywords: Small cell lung cancer; PARP inhibitors; immune
checkpoint blockade; tumor immune phenotype; DNA
repair

Introduction
SCLC is the most aggressive and lethal form of lung
cancer. It represents 15% of all lung cancers, with an
annual incidence of more than 34,000 cases in the United
States. SCLC is characterized by rapid doubling time, high
growth fraction, and early and widespread metastatic
involvement.1 Although response rates to ﬁrst-line platinum-based chemotherapy are exceptionally high, tumor
usually recurs in months. Additional chemotherapy is
usually ineffective at relapse, and fewer than 5% of patients with extensive-stage SCLC survive 2 years.
Despite recent advances in immune checkpoint
blockade, only a minority of patients with SCLC beneﬁt
from these therapies. Nivolumab, an anti–programmed
death 1 (PD-1) antibody yielded objective response
rates (ORRs) of 10% and median overall survival (OS) of
4.4 months in previously treated patients with SCLC.2
Although efﬁcacy is better in programmed death-ligand
1 (PD-L1)-positive SCLC and with combined immune
checkpoint blockade, these approaches are applicable in
only a limited number of patients and are associated
with substantial toxicities.2–4
One approach to augment the clinical activity of immune checkpoint inhibitors is to modulate the DNA
damage response (DDR).5 Poly (ADP-ribose) polymerase
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(PARP) 1 is highly expressed in SCLC, and PARP inhibitors have shown antitumor activity in both preclinical models of and patients with SCLC.6–9 Preclinical
observations suggest that combination of immune
checkpoint blockade with PARP inhibition may be an
effective therapeutic strategy.10–12 PARP inhibition
potentiated the antitumor effect of PD-L1 blockade and
augmented cytotoxic T-cell inﬁltration in multiple
immunocompetent SCLC models.13 Accumulating evidence also suggests that DNA double-strand break and
cytosolic DNA can induce PD-L1 expression through
mechanisms including a stimulator of interferon gene–
mediated innate immune response.10,14–16
Durvalumab (MEDI4736) is a selective, high-afﬁnity
human immunoglobulin G1 monoclonal antibody that
blocks PD-L1 binding to PD-1 and CD80, thereby
enhancing the function of tumor-directed T cells.17
Durvalumab is approved for metastatic urothelial carcinoma and unresectable stage III NSCLC after chemoradiation. The PARP inhibitor olaparib blocks the DNA
repair function of these enzymes and traps inactivated
PARP onto single-strand DNA breaks, preventing repair
and generating a DNA replication block and leading to
DNA double-strand break.18 Olaparib is approved for
epithelial ovarian cancers and germline (BRCA1, DNA
repair associated gene [BRCA])-mutated metastatic
breast and ovarian cancers. We previously established
the safety and tolerability of a combination of durvalumab and olaparib in a phase I trial.19 No dose-limiting
toxicities were observed and the most common
adverse events (AEs) were hematologic, which were
manageable with supportive care.
We hypothesized that PARP inhibition could render
SCLC more susceptible to immune checkpoint blockade
and expanded the phase II trial of durvalumab and olaparib to enroll a cohort of patients with SCLC. The primary
objective was to determine antitumor activity in patients
with relapsed SCLC. Mandatory fresh biopsy specimens
were obtained at baseline and during treatment to assess
the dynamic changes in T-cell inﬁltration and PD-L1
expression before and during treatment. Here we report
the efﬁcacy, safety, and biomarker results from patients
with SCLC treated with durvalumab plus olaparib.

Patients and Methods
Eligible patients had histologically conﬁrmed SCLC
and one or more platinum-based chemotherapy treatments. Other eligibility criteria included an Eastern
Cooperative Oncology Group performance status of 2 or
lower and adequate organ/bone marrow function. Previous therapy with an immune checkpoint inhibitor was
not an exclusion. Patients with both platinum-sensitive
(progression 90 days from last platinum dose) and

August 2019

platinum-resistant/refractory (progression <90 days)
disease were eligible. Key exclusion criteria were previous treatment with PARP inhibitors, symptomatic
brain metastases, autoimmune disease requiring steroids, pneumonitis and/or interstitial lung disease, or
inﬂammatory bowel disease. The trial was conducted
under a National Cancer Institute Center for Cancer
Research–sponsored investigational new drug application with institutional review board approval. Written
informed consent was obtained from all patients
(ClinicalTrials.gov identiﬁer NCT02484404).

Study Design and Treatment
This was an open-label, single-arm phase II study of a
combination of durvalumab and olaparib in patients
with relapsed SCLC (Fig. 1A). Treatment cycles were 28
days long. Durvalumab (1500 mg) was administered
intravenously every 28 days. Olaparib tablets (300 mg
twice daily) were administered continuously.

Efﬁcacy and Safety Evaluations
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with direct proximity between cancer and immune cells),
stromal (in the surrounding connective tissues and blood
vessels), or peritumoral (around the tumor at the advancing
margin of the tumor, in the stroma or the tissues adjacent to
the tumor). On the basis of the presence of CD3-positive and
CD8-positive T cells and the pattern of inﬁltration with
respect to tumor cells, tumors were categorized into
immunophenotypes as described previously20: “desert”
when the prevalence of CD8-positive T cells was low,
“excluded” if CD8-positive T cells were exclusively seen in
stroma immediately adjacent to or within the tumor, or
“inﬂamed” if CD8-positive T cells were seen in direct contact with tumor cells either in the form of spillover of
stromal inﬁltrates into tumor cell aggregates or in the form
of diffuse inﬁltration of CD8-positive T cells in aggregates or
sheets of tumor cells.
Plasma cytokines were assessed before treatment, at
cycle 1 day 15, and at cycle 3 day 1. Circulating free-DNA
was assessed in selected patients. Methodological details
are provided in the Supplementary Data.

Statistical Methods

A history and physical examination were conducted
at baseline and before each cycle. Complete blood counts
with differential and serum chemistries were performed
at baseline, 2 weeks later, and before each cycle.
Radiographic evaluation was performed at baseline and
every two cycles, and tumor response was assessed on
the basis of the Response Evaluation Criteria in Solid
Tumors, version 1.1. Toxicities were graded by using the
National Cancer Institute Common Terminology Criteria
for Adverse Events, version 4.0). Given reports of
neurological immune-related AEs in patients with SCLC
who were receiving immune checkpoint inhibitors,2 patients underwent baseline and follow-up neurological
examinations by an expert in neuromuscular disorders,
as needed.

The primary end point was ORR. Progression-free
survival (PFS), deﬁned as time from start of treatment
to time of progression or death, and safety were secondary end points. Identiﬁcation of biomarkers of
response was an exploratory end point. The trial was
conducted with use of an optimal two-stage phase II trial
design to rule out an unacceptably low ORR rate of 15%
in favor of an improved response rate of 35% with an
alpha value of 0.10 and beta value of 0.10. Futility was
deﬁned as zero to three responses in the ﬁrst 19 patients; accrual would continue to 33 patients if there
were four or more responses in the ﬁrst stage. PFS, OS,
and duration of response were calculated by using the
Kaplan-Meier method.

Tumor Biopsies and Correlative Studies

Results

.Patients underwent mandatory pretreatment and
optional during-treatment biopsy (2–4 weeks after treatment, with the specimen taken from the same location)
(see Fig. 1A). Five-micron sections of formalin-ﬁxed,
parafﬁn-embedded tissue were assessed for PD-L1
expression and T-cell inﬁltration by immunohistochemistry with use of the following antibodies and detection
methods: PD-L1 (1:3 dilution, clone SP142 [Springer Biosciences], Leica Bond [Leica Biosystems]), CD3 (predilute,
clone 2GV6, Ventana and Ventana BenchMark Ultra
[Ventana Medical Sytems]), and CD8 (1:25, clone CD8/
144B [Dako], Ventana BenchMark Ultra [Ventana Medical
Systems]) following the manufacturer’s protocol.
The location of tumor-inﬁltrating T cells was noted as
follows: intratumoral (within the mass of tumor cells,

Patient Demographics
Between April 2016 and June 2018, a total of 20
patients with extensive-stage SCLC were enrolled
(Table 1). The median age of the patients was 64 years
(range 42–76). All patients had received prior chemotherapy and had disease progression at enrollment. Ten
patients (50%) had two or more prior lines of therapy.
Most patients (60%) had platinum resistant/refractory
disease. All patients had received platinum plus etoposide as ﬁrst-line treatment; 30% had received secondline or later treatment with topotecan, temozolomide
or paclitaxel; and 15% had received prior immune
checkpoint blockade.
All patients were evaluable for safety. A median of
two cycles of treatment was administered (range 1–12
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A
Relapsed SCLC patients treated with
durvalumab plus olaparib (N=20)

Pretreatment
• Tumor biopsy (N=19)
• Blood (N=18)

On-treatment
• Tumor biopsy after 2-4 weeks (N=10)
• Blood (C1D15: N=18; C2D1 N=13)
Analysis
• PD-L1 expression (IHC)
• CD3+ and CD8+ T-cell infiltration (IHC)
• Plasma cytokines (immunoassay)

Immunophenotyping and correlation
with clinical responses

Figure 1. Efﬁcacy of durvalumab plus olaparib in relapsed SCLC. (A) Study schema and biomarker analyses. (B) Waterfall plot
showing change of tumor burden from baseline (investigator assessed [n ¼ 19]). One patient was not evaluable for response
because of rapidly PD before the ﬁrst restaging scans. Bar length represents decrease or increase in target lesion size. Bar
color is the best overall response (according to the Response Criteria in Solid Tumors [RECIST], version 1.1). Indicated by
asterisk is a patient who discontinued treatment after one cycle for brain-only disease progression but had a partial response
(PR) in the systemic disease-sites that lasted 6 months with no additional systemic therapy. Boxes above the waterfall plot
indicate the smoking status, platinum sensitivity, RECIST response, programmed death ligand 1 (PD-L1) expression and
immunophenotype of pretreatment tumors. (C) Spider plot of change in the sum of the unidimensional tumor measurements
over time. The red lines represent conﬁrmed responders, blue lines represent patients with PD, and gray lines represent
patients with stable disease. Light brown squares indicate the time points at which patients discontinued treatment because
of progressive disease in the brain. Plus sign indicates patients who are receiving treatment at data cutoff. Asterisk indicates
the patient who discontinued treatment after one cycle for brain-only disease progression but who had a PR in the systemic
disease-sites. One patient who was not evaluable is not included. IHC, immunohistochemistry.

cycles). A total of 19 patients were evaluable for
response. One patient was not evaluable for response
because of rapidly progressive disease (PD) before the
ﬁrst restaging scans. At the time of data cutoff on
October 1, 2018, the median follow-up time was 11.1
months (range 4.0–29.8). Three patients are continuing
to receive treatment.

Efﬁcacy
Of the 19 evaluable patients, one each had a conﬁrmed
complete response (CR) and a partial response (PR) and
four patients had stable disease, including two instances
of prolonged stable disease (8 months) (Fig. 1B and C
and Supplementary Table 1). In all, 13 patients had PD.
This included a patient who discontinued treatment after
one cycle for brain-only disease progression but had a PR
in the systemic disease sites that lasted 6 months with no

additional systemic therapy, as well as another patient
who had a PR at the ﬁrst restaging but PD on the
conﬁrmatory scan. The investigator-assessed ORR was
10.5% (95% conﬁdence interval [CI]: 1.3%–33.1%). The
median PFS was 1.8 months (95% CI: 0.9–2.4 months),
and the 6-month PFS probability was 20.0% (95% CI:
6.2%–39.3%) (Supplementary Fig. 1). The median OS
was 4.1 months (95% CI: 2.4–9.2 months), and the
6-month OS rate was 37.1% (95% CI: 16.3–58.2%)
(Supplementary Fig. 2). All told, clinical beneﬁt was
observed in four of 19 (21.1% [95% CI: 6.1%–45.6%])
evaluable patients who had conﬁrmed CR, PR, or prolonged stable disease (8 months).
The patient with the CR (patient 6) had platinumrefractory disease that harbored a deleterious BRCA1
mutation. The rapid clinical improvement in this patient
was accompanied by a steep decline in circulating free
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Table 1. Patient Characteristics (N ¼ 20)
Characteristic
Sex, n (%)
Female
Male
Median age, y (range)
ECOG performance status, n (%)
0
1
2
Race, n (%)
White
Asian
Black
Type of prior therapy, n (%)a
Chemotherapy
Radiotherapy
Immunotherapy
Surgery
Investigational agents
Lines of prior systemic therapy, n (%)
1
2
3
Prior chemotherapy type, n (%)
Cisplatin/carboplatin plus etoposide
Topotecan
Paclitaxel
Temozolomide
Sensitivity to ﬁrst-line therapy
Platinum-sensitive
Platinum-resistant/refractory

Value
11 (55)
9 (45)
64 (42–76)
1 (5)
18 (90)
1 (5)
18 (90)
1 (5)
1 (5)
20 (100)
9 (45)
3 (15)
1 (5)
4 (5)
10 (50)
7 (35)
3 (15)
20 (100)
3 (15)
2 (10)
1 (5)
8 (40)
12 (60)

a

Patients could have received more than one type of prior therapy.
ECOG, Eastern Cooperative Oncology Group.

DNA (Fig. 2A and B). The patient discontinued treatment
after 11 months for relapse limited to the brain. As of the
last follow-up at 21 months after the start of treatment,
the patient continued to have no evidence of systemic
disease.
The patient with the conﬁrmed PR (patient 19) had
EGFR-mutant adenocarcinoma transformed to SCLC and
was continuing to receive treatment, with the response
maintained for 5 months at the time of data cutoff.
Two patients, each of whom had previously received
immune checkpoint inhibitors (patients 15 and 16, who
previously had PD after 4 and 6 months of immune
checkpoint inhibitor-combination, respectively), had
prolonged stable disease ongoing at 8 months each.
Finally, an additional patient (patient 11) discontinued
treatment after one cycle for brain-only disease progression. This patient later had a systemic response that
was maintained for 6 months until disease progression.

Safety
Treatment-related AEs are listed in Table 2. The most
common AEs were anemia (80%), lymphopenia (60%),

Vol. 14 No. 8

leukopenia (50%), and fatigue and thrombocytopenia
(45% each). Nine patients (45%) had grade 3 or 4
treatment-related AEs: anemia, lymphopenia, thrombocytopenia, and hypophosphatemia. No neurological or
immune-related AEs were observed except for an
increased level of thyroid-stimulating hormone (25%),
which was asymptomatic in all cases. One patient needed
dose reduction of olaparib for grade 3 anemia. No
additional dose modiﬁcations were required, and no
patient discontinued treatment because of AEs.

PD-L1 Expression and Tumor-Inﬁltrating Immune
Cells
Of the 19 patients, all except one (who was considered high-risk for biopsy because of clinical deterioration since screening) underwent biopsy to collect fresh
pretreatment core biopsy specimens. Eight of the 18
patients (44%) with adequate tissue for evaluation had
quantiﬁable PD-L1 expression in tumor cells or tumorinﬁltrating immune cells (Supplementary Table 2); in
most cases, it was limited to less than 20% of cells. An
inﬂamed phenotype was usually accompanied by PD-L1
expression. PD-L1 was expressed in tumor or stroma in
both of the patients with conﬁrmed responses (patients
6 and 19) and in a patient with systemic response and
brain-only PD (patient 11). However, PD-L1 expression
was also noted in several tumors that did not respond. In
contrast, tumor responses were observed in all instances
when pretreatment tumors showed an inﬂamed phenotype (patients 6, 19, and 11) (see Fig. 1A). None of the
noninﬂamed tumors responded to treatment.
To characterize the immunological events associated
with tumor response or progression, during-treatment
tumor biopsies were performed in 10 patients, of
which nine provided adequate material (Supplementary
Table 2). Responding tumors (those of patients 11 and
19) displayed a dense T-cell inﬁltrate in clusters and
aggregates extending deeply into the tumor with extensive tumor cell necrosis accompanied by increased
PD-L1 expression on tumor and tumor-inﬁltrating immune cells (Fig. 3A). In contrast, nonresponding tumors
showed a lack of PD-L1 expression and displayed either
an immune desert (minimal or no T-cell inﬁltration)
(Fig. 3B) or immune-excluded pattern (T cells solely
around the outer edge of the tumor) (Fig. 3C).
Changes in PD-L1 expression and T-cell inﬁltration
are described in Supplementary Table 2. Of the ﬁve
patients having tumors with no pretreatment PD-L1
expression, two (patients 9 and 12) remained negative
for PD-L1 expression after treatment; in three (patients
10, 13, and 20), PD-L1 expression was seen on tumor
cells after treatment with no expression on tumorinﬁltrating immune cells. In all ﬁve cases, no signiﬁcant
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Figure 2. Representative responses. (A) Computed tomography images and (B) dynamic changes in circulating free DNA at
the corresponding time points in a patient with a complete response (patient 6). The right supraclavicular lymph node is
indicated by red circles. TP53, tumor protein p53 gene; BRCA1, BRCA1 associated protein 1 gene; NFKB2, nuclear factor
kappa B subunit 2 gene.

Table 2. Treatment-Related Adverse Events (Maximum
Grade, All Cycles) (N ¼ 20 Patients)
Grade
Adverse Event

1

2

3

4

Total (%)

Anemia
Lymphocyte count
decreased
White blood cell decreased
Platelet count decreased
Fatigue
Hypothyroidism
Vomiting
Nausea
Diarrhea
Neutrophil count
decreased
Anorexia
Constipation
Gastroesophageal reﬂux
disease
Hypophosphatemia
Alanine aminotransferase
increased
Alkaline phosphatase
increased
Dysgeusia
Dyspepsia
Headache
Hypomagnesemia

7
3

7
4

2
3

2

16 (80)
12 (60)

6
7
7
5
4
3
3
2

4
1
2

1

2
2
2

10 (50)
9 (45)
9 (45)
5 (25)
4 (20)
3 (15)
3 (15)
2 (10)
2 (10)
2 (10)
2 (10)

1
1

2 (10)
1 (5)

1

1 (5)

1
1
1
1

1

1
1
1
1

(5)
(5)
(5)
(5)

changes in the T-cell inﬁltration pattern were observed;
T cells were limited to the stroma and peritumoral area
both before and after treatment. Of four tumors with
pretreatment PD-L1 expression on tumor cells or tumorinﬁltrating immune cells, three cases showed substantial
increase in the number and intensity of PD-L1–positive
cells, which in two instances were associated with clinical response (in patients 11 and 19).

Cytokines
Treatment resulted in increased concentrations of
inﬂammatory
cytokines,
notably
IFN
gamma,
interleukin-6, and interleukin-10, which is indicative of a
systemic immune activation (Supplementary Fig. 3).
Cytokine levels at baseline and change with treatment
were not signiﬁcantly associated with clinical response.

Discussion
Patients with SCLC continue to have one of the worst
survival rates of all patients with cancer. Response to
immune checkpoint blockade is relatively low despite a
high tumor mutational burden. This study was conducted on the basis of preclinical data suggesting a
beneﬁcial interaction between DDR inhibition and immune checkpoint blockade and an extension of our
previous work that deﬁned the safety and tolerability of
the combination of durvalumab and olaparib.19 To our
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Figure 3. Biomarker status and responses. SCLC immunophenotypes visualized on pretreatment and during-treatment (2–4
weeks later) biopsy specimens stained immunohistochemically for the presence of programmed death ligand 1 (PD-L1) and
CD3-positive and CD8-positive T cells. (A) Immune inﬂamed phenotype in a patient with transformed SCLC (patient 19) and an
ongoing partial response. Pretreatment and during-treatment biopsy specimens stained immunohistochemically for the
presence of PD-L1, CD3-positive, and CD8-positive T cells (original magniﬁcation 40). (B) Immune desert phenotype in a
patient who had progressive disease (patient 20). Pretreatment and during-treatment tumors show no T-cell inﬁltration or
PD-L1 expression (original magniﬁcation 10). (C) Immune-excluded phenotype in a patient (patient 9) with arrows indicating the tumor-stroma margin with T-cell inﬁltration after treatment (original magniﬁcation 10). HE, hematoxylin and
eosin.

knowledge, this is the ﬁrst published report to evaluate
immune checkpoint inhibitors with PARP inhibitor in
patients with relapsed SCLC.
The study did not meet its primary end point, and the
ORR of 10.5% failed to reject the null hypothesis of 35%.
The conﬁrmed ORR is similar to that of the PD-1 inhibitor nivolumab alone in this setting.2 Clinically meaningful antitumor activity was observed in 21% of
patients (conﬁrmed CR, PR, or prolonged stable disease
lasting 8 months), and no unexpected safety signals
were detected. Two of three patients who had previously
received immune checkpoint inhibitors had prolonged
stable disease and were continuing to receive treatment
at 8 months at the time of data cutoff.

The objective responses in this study occurred in
patients with identiﬁable genomic alterations. The patient with a CR had a deleterious somatic BRCA1 mutation. It is possible that the DDR defect sensitized
the tumor to PARP inhibition, yet the depth and durability of tumor regression suggest a contribution from an
immune-mediated response. An association between
DDR gene alterations and improved responses to immune checkpoint inhibitors has been reported in urothelial cancers20 and melanoma.21 The frequency of DDR
alterations in SCLC and whether there is an association
between DDR alterations and immune checkpoint inhibitor response need further study. The prolonged
ongoing response in a patient with EGFR-mutant NSCLC
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that transformed to SCLC is notable in light of a recent
report that found no responses among 17 patients with
transformed SCLC who received immune checkpoint inhibitor alone.22 The results of this study are in line with
the ﬁndings from a phase II basket study in which olaparib was administered as monotherapy for 4 weeks
followed by combination with durvalumab in patients
with relapsed SCLC at least 12 weeks after platinumbased therapy.23 Among 38 patients, two (5%) had responses and the 12-week disease control rate was 29%.
Deﬁning biomarkers predictive of response in SCLC is
challenging because in this disease, biopsies are generally not performed at relapse and biopsy specimens
usually provide limited tissue for analyses. Further, the
relevance of the tumor immune phenotype to the
response of SCLC was previously unknown. Consistent
with the published literature, we observed that PD-L1
expression was in most cases limited to a minority of
tumor cells and or tumor-inﬁltrating immune cells.24 In
our cohort, a large proportion of tumors (64%) exhibited
the excluded phenotype; by contrast, only 21% and 14%
of tumors exhibited the inﬂamed and desert phenotypes,
respectively. Tumor responses were observed in all
cases in which pretreatment tumors were T-cell–
inﬂamed. Tumor CD8-positive T-cell inﬁltration has been
linked to antitumor activity in patients with advanced
melanoma25 and NSCLC26 treated with immune checkpoint inhibitors. Our observation extends these ﬁndings
to relapsed SCLC and suggests that a preexisting CD8positive T-cell response may be predictive of beneﬁt
from immune checkpoint inhibitor-based therapies in
SCLC. If conﬁrmed in larger cohorts, these ﬁndings may
help identify those patients with SCLC who are most
likely to beneﬁt from immune checkpoint inhibitor–
based therapies.
To our knowledge, this study is the ﬁrst to assess
immune phenotypes in serial SCLC biopsy specimens
obtained during treatment. Biopsy specimens were obtained from the same lesion to minimize biological
variability. Several observations are worth highlighting:
ﬁrst, the regressing lesions had a preexisting immune
response and after treatment showed dense T-cell inﬁltration, suggesting that preexisting immunity is further
ampliﬁed during treatment when responses do occur.
Second, several nonresponding tumors had minimal or
no tumor-inﬁltrating immune cells before and after
treatment, likely reﬂecting the absence of preexisting
tumor-speciﬁc T cells. Downregulation of human leukocyte antigen class I, which reduces the number of T-cell
targets among the potential pool of aberrantly expressed
tumor antigens, has been documented in SCLC27 and
may perhaps be operational here. Third, some of the
nonresponding tumors showed a pattern wherein the
immune cells did not penetrate the tumor but were
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instead restricted to the stroma, likely reﬂecting the
presence of immunosuppressive mechanisms within the
tumor. Finally, treatment with the combination did not
result in substantial induction of PD-L1 in the nonresponding phenotypes or induction of an immune
response where there was no preexisting immune
response. It is unlikely that the lack of PD-L1 induction
was due to sampling time points, as patients received
continuous twice-daily dosing of olaparib that should
have resulted in continuous PARP inhibition.
Potential limitations of this trial are its small sample
size and its single-arm design with no monotherapy
comparator groups, thereby preventing direct comparison of the combination with either agent alone.
Lack of a comparator group also limits our ability to
attribute the relative contribution of both drugs to the
clinical and biomarker response. The relevance of the
genomic proﬁle to responses cannot be assessed in this
study because such information is not available for
nonresponding patients. Conclusions regarding the
tumor microenvironment are limited by the sample
size and the core biopsy size, which limits our understanding of the heterogeneity of immune responses
among tumor sites. Nevertheless, the ﬁndings highlight
the importance of serial biological proﬁling of
SCLC over time at different treatment decision points.
The combination of PARP inhibition and immune
checkpoint blockade is being investigated in multiple
tumor types, including prostate, ovarian, NSCLC,
and breast cancers (NCT02734004, NCT02657889,
NCT03330405, and NCT02484404). Preliminary results suggest that the improved combinatorial activity
may be tissue speciﬁc.28
In conclusion, although the trial did not meet its
primary end point, examination of pretreatment and
during-treatment biopsy specimens provides important
insights into selection of patients with SCLC for immune
checkpoint inhibitor–based approaches. Rational development of immunotherapy combinations remains a challenge, particularly so in SCLC, where tissue availability
presents a major obstacle to progress. Optimal immunotherapy in SCLC may need to enhance not only T-cell
function but also antigen presentation and may also need
to target the immunosuppressive mechanisms in the
tumor microenvironment.29
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